StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Premarin Family [legacy through FY24] by Year

Premarin Family (conjugated estrogens) [legacy through FY24] — Worldwide operational (constant-currency) YoY (%) (%)

Pfizer Premarin Family [legacy through FY24]: -4.0% in FY2024, down 11.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2024
-4.0%
Period ended Dec 31, 2024
Change on a year earlier
-11.0 pts
7.0% in FY2023
History
8 years
Since FY2017
Sources
8
Documents cited below

Where the FY2024 figure comes from

“|| Premarin family | 380 | 397 | (4%) | (4%) | 341 | 361 | (5%) | 39 | 36 | 8% | 9%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Pfizer Premarin Family [legacy through FY24] (%), annual FY2017–FY2024 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/premarin-leg-oper-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.